

1646 \$  
#10/B  
Dawn  
2/14/02  
RECEIVED  
FEB 07 2002  
TECH CENTER 1600/2900

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:


Shaughnessy et al.  
Serial No: 09/491,982  
Filed: January 27, 2000  
For: OSTEOPOROSIS TREATMENT

Attorney Docket No. MDSP-P02-180  
Art Unit: 1646  
Examiner: Prasad, S.

**CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)**

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail, postage prepaid, in an envelope addressed to: Assistant Commissioner for Patents Washington, D.C. 20231 on the date indicated below:

January 16, 2002  
Date of Signature  
and of Mail Deposit

  
Dawn Harmon

Assistant Commissioner of Patents  
Washington, D.C. 20231

**REPLY UNDER 37 CFR 1.111**

Sir:

In response to the Office Action mailed July 16, 2001, in connection with the above application, Applicants submit this reply. The time period for response has been extended to January 16, 2002, by the accompanying petition for a three-month extension of time. Please enter the following amendments:

In the specification:

On page 10, please replace the entirety of the last full paragraph with:

*B,*  
Additionally, SEQ ID NO. 6 depicts the amino acid sequence of an IL-11 binding region identified within the human IL-11R, namely: Ser Ile Leu Arg Pro Asp Pro Pro Gln Gly Leu Arg Val Glu Ser Val Pro Gly Tyr Pro. The corresponding murine sequence is depicted in SEQ ID NO. 8 and is: Ser Ile Leu Arg Pro Asp Pro Pro Gln Gly Leu Arg Val Glu Ser Val Pro Ser Tyr Pro. These sequences differ in their eighteenth amino acid whereby the human peptide has Gly and the murine sequence has Ser. Gly and Ser are both relatively small amino acid residues, having